More and more data are being collected on people and in healthcare, patients have to believe that the data being collected is for their good and with the goal of improving their care, said John Frownfelter, MD, FACP, chief medical officer of Jvion.
More and more data are being collected on people and in healthcare, patients have to believe that the data being collected is for their good and with the goal of improving their care, said John Frownfelter, MD, FACP, chief medical officer of Jvion.
Transcript
How can healthcare balance the pros and cons consumers see when they think about all the data being collected on them?
Well, the data is out there. I think there is a sense of the public trust having been violated and at the same time everybody acknowledges—I’ve got a lot of friends, especially younger generation, like “Yeah, they collect it and I don’t care. I have Alexa and I have Google in my home, and I know they’re collecting data on me and I don’t care.”
So, is healthcare data really any different? Or is the fact that we’re using social data that we can get on a patient to improve the care that we’re delivering, is that a bad thing? Or is that a good thing? That’s the kind of question that should be raised and debated, but in general, one of the guiding principles there is beneficence, and the good intention behind having that data in order to render better care is certainly noble.
So, at the end of the day, in healthcare, I think we win the ethical discussion and we are certainly in a better position than say the big industry tech giants that are using it for profit.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More